

PATENT Attorney Docket No. MDS-033C1 (120407/156567)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS:

Schomacker et al.

CONFIRMATION NO.: 7328

SERIAL NO.:

10/848,735

GROUP NO.:

2884

FILING DATE:

May 19, 2004

EXAMINER:

Sung, Christine

TITLE:

METHOD AND APPARATUS FOR IDENTIFYING

SPECTRAL ARTIFACTS

Terminal Disclaimer

I, Stephen L. Watson, residing at 45 Hartwell Avenue, Lexington, MA 02421, state that I am a representative authorized to sign on behalf of MediSpectra, Inc., identified below as the assignee of the entire right, title and interest in and to the above-identified patent application, U.S. Serial No. 10/848,735. I have reviewed all the evidentiary documents accompanying or referred to in the instant Terminal Disclaimer and certify that, to the best of my knowledge and belief, title to the above-identified application is in the name of MediSpectra, Inc.

MediSpectra, Inc., of 45 Hartwell Avenue, Lexington, MA 02421, is the assignee of the entire right, title and interest in and to the above-identified application, 10/848,735, by virtue of an assignment from the inventors to MediSpectra, Inc., that was recorded in the United States Patent and Trademark Office at Reel 016229, Frame 0271, on February 4, 2005.

MediSpectra, Inc., hereby waives and disclaims the terminal part of any patent granted on the above-identified application, U.S. Serial No. 10/848,735, which would extend beyond the full statutory term of U.S. Patent No. 6,818,903, which issued from U.S. Serial No. 10/243,535 on November 16, 2004, and hereby agrees that any patent so granted on U.S. Serial No. 10/848,735 shall be enforceable only for and during such period that the patent is commonly owned with U.S. Patent No. 6,818,903. This agreement runs with any patent granted on the instant application and is binding upon the Assignee, its successors or assigns.

Terminal Disclaimer U.S. Serial No. 10/848,735 Page 2 of 2

MediSpectra, Inc., does not disclaim any terminal part of the term of any patent granted on the instant application, U.S. Serial No. 10/848,735, prior to the expiration date of the full statutory term of U.S. Patent No. 6,818,903 in the event that U.S. Patent No. 6,818,903 expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 C.F.R. 1.321(a), has all claims canceled by a re-examination certificate, is reissued, or is otherwise terminated prior to expiration of its statutory term as presently shortened by any terminal disclaimer.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements are made in the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

MediSpectra, Inc.
By Stephen Lutison
Name Stephen L. Watson
Title President & CEO
Date 10/15/06